Repligen

Repligen Appoints Maggie A. Pax to Board of Directors

Retrieved on: 
화요일, 3월 19, 2024
College, Innovation, Growth, Life Technologies, Repligen, Business, MIT, Thermo Fisher Scientific, Harvard Business School, Strategic planning, Business development, Acquisition, Massachusetts Institute of Technology, MBA, Marketing, Holy Cross, Alimera Sciences, Corporation, Management

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.
  • Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies.
  • Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We’re very happy to welcome Maggie Pax as a terrific addition to the Repligen Board with extensive experience in the life sciences industry.
  • Hunt, Chief Executive Officer for Repligen said, “Maggie understands first-hand the drivers of growth for our industry and has touched many of the focus areas for Repligen: key account programs, continuous innovation and M&A integration.

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
수요일, 2월 21, 2024
Acquisition, Filtration, Ultrafiltration, Growth, Loss, ESG, Cross-flow filtration, GAAP, Net, TFF, Repligen

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023.

Key Points: 
  • WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023.
  • We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter.
  • Base revenue (non-GAAP) for Q4 2023 was $142.1 million, compared to $163.0 million for Q4 2022.
  • For Q4 2023, net loss (GAAP) was ($25.5) million, compared to net income (GAAP) of $48.7 million for Q4 2022.

Slingshot Biosciences Announces Election of Nicolas Barthelemy as Executive Chair

Retrieved on: 
수요일, 1월 24, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Engineering, Life Technologies, Patient, Therapy, Senior management, UC, Repligen, University of California, Berkeley, Biogen, Chemical engineering, Growth

Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair.

Key Points: 
  • Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair.
  • “We have been working closely with Nicolas over the last two years and are excited to bring his experience, operational expertise, and strategic insights to bear on this next phase of our growth,” said Dr. Jeffrey Kim - CEO & President of Slingshot Biosciences.
  • Nicolas also currently holds board positions at Repligen, Inc., Biocare Medical, and Nanocellect.
  • With end-applications ranging from Research and Bioprocessing to Hematology, Diagnostics and Therapeutics, we have the opportunity to build a company that could meaningfully impact a very broad area of Life Sciences,” said Nicolas Barthelemy.

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

Retrieved on: 
목요일, 12월 7, 2023
Sale, Transaction, Repligen, Debt-to-GDP ratio, Investment, Perella Weinberg Partners, Bank

Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”).

Key Points: 
  • Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”).
  • Following the closing of the Transactions, which is expected to occur on or about December 14, 2023, approximately $69.7 million in aggregate principal amount of 2024 Notes will remain outstanding with terms unchanged.
  • Repligen anticipates the cash proceeds from the Subscription Transactions will be approximately $276.2 million, after subtracting fees and estimated expenses in connection with the Transactions.
  • The increase reflects the cash proceeds from the Subscription Transactions, net of fees, estimated expenses and the share repurchases associated with the Subscription Agreements.

UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report

Retrieved on: 
화요일, 11월 14, 2023
Sustainable Development Goals, Sustainability reporting, Repligen, Sustainability, TCFD, UN, Climate, Zero trust security model, Benchmarking, Science Based Targets initiative, GRI, Carbon accounting, GHG, Letter, CDP, United Nations, ESG, Renewable energy, Oil, Woman

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.

Key Points: 
  • WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.
  • Themed “ Making an Impact ”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “ Committed to Making a Difference ”.
  • Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).
  • Tony Hunt, Chief Executive Officer at Repligen said, “Our initial Sustainability report published in 2021 elevated awareness in the company and prompted higher levels of action across the ESG spectrum.

Repligen Announces Publication of the Company’s 2022 Sustainability Report

Retrieved on: 
화요일, 11월 14, 2023
Sustainable Development Goals, Sustainability reporting, Repligen, Sustainability, TCFD, UN, Climate, Zero trust security model, Benchmarking, Science Based Targets initiative, GRI, Carbon accounting, GHG, Letter, CDP, United Nations, ESG, Renewable energy, Oil, Woman

WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.

Key Points: 
  • WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.
  • Themed “ Making an Impact ”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “ Committed to Making a Difference ”.
  • Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).
  • Tony Hunt, Chief Executive Officer at Repligen said, “Our initial Sustainability report published in 2021 elevated awareness in the company and prompted higher levels of action across the ESG spectrum.

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

Retrieved on: 
목요일, 11월 2, 2023
Filtration, Dicarboxylic acid, Repligen Corporation Award in Chemistry of Biological Processes, Chromatography, CNC, Senior, Repligen, Cross-flow filtration, Risk, Spacecraft, Ultrafiltration, Safety, PRO, TFF, SC, Cassette tape

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device.

Key Points: 
  • WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device.
  • Christine Gebski, Senior Vice President, Filtration and Chromatography at Repligen, said, “TangenX SC pushes the boundaries of TFF innovation, offering clear advantages to virtually any user of flat sheet TFF.
  • The holder-free TangenX SC device simplifies and streamlines downstream flat sheet UF/DF processes like never before.
  • Designed with the same flow path length and channel geometry as traditional cassettes, TangenX SC allows users to seamlessly transition from traditional cassettes.

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Retrieved on: 
화요일, 10월 31, 2023
Sale, Tax, SG, EBITDA, GAAP, Acquisition, Bank statement, Repligen, COVID, Stock, COVID-19, Income tax, Webcast, Depreciation, 2020–2022 Chinese property sector crisis, Table, Commercial property, Bank

As previously disclosed, in July 2023 we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations.

Key Points: 
  • As previously disclosed, in July 2023 we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations.
  • ET, to discuss third quarter 2023 financial results, corporate developments and financial guidance for the year 2023.
  • A reconciliation of GAAP to adjusted (non-GAAP) financial measures is included as an attachment to this press release.
  • When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

Global Downstream Processing Market Size, Share & Trends Analysis Report 2023: Chromatography Systems Segment Dominated in 2022 with 41.29% Market Share - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
금요일, 10월 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Infectious Diseases, Clinical Trials, Food and Bioprocess Technology, Purification, Vaccine, Government, Membrane, Acquisition, Application, Repligen, Growth, COVID-19, Filter, Partnership, Traction, USD, Investment, Titanium, Chromatography, Automation, Fine chemical, Speciality chemicals, Pharmaceutical industry

The "Downstream Processing Market Size, Share & Trends Analysis Report By Product (Chromatography Systems, Filters), By Technique (Purification, Formulation), By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Downstream Processing Market Size, Share & Trends Analysis Report By Product (Chromatography Systems, Filters), By Technique (Purification, Formulation), By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global downstream processing market size is expected to reach USD 94.79 billion by 2030.
  • This expansion is set to unfold at an impressive compound annual growth rate (CAGR) of 14.84% from 2023 to 2030.
  • Notably, the surge in downstream processing techniques' adoption for COVID-19 vaccine development has played a pivotal role in propelling market growth.

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

Retrieved on: 
월요일, 10월 2, 2023
Improper integral, ASIA, Genomics, Lonza, Danaher, MBA, CCO, Business administration, Repligen, Repligen Corporation Award in Chemistry of Biological Processes, Growth, Bioprocess, Emlyon Business School, Fine chemical, Management, Basel, Chemistry

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.

Key Points: 
  • WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.
  • Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing.
  • Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets.
  • Hunt, Chief Executive Officer at Repligen, said, “We are delighted to welcome Olivier to our team at Repligen.